CareDx, Inc. (Nasdaq: CDNA) completed the sale of its Lab Products business to Eurobio Scientific on June 30, 2026, receiving $171.2 million in cash at closing, subject to customary post-closing adjustments, according to a press release from the company.

The transaction received required Swedish regulatory clearance before closing. The divested business includes in vitro diagnostic PCR kits for deceased donor HLA typing, NGS-based kits for transplant recipient HLA typing globally, and NGS-based monitoring assays for solid organ and stem cell transplant recipients outside of North America.

"This transaction sharpens CareDx's focus on our core U.S. Precision Medicine Testing Services and Patient and Digital Solutions, where our integrated model continues to deliver strong growth," said John Hanna, President and Chief Executive Officer of CareDx. "It also simplifies our operating model and supports our disciplined approach to capital allocation, including investments that expand our capabilities in high-growth areas such as specialty oncology."

CareDx said it plans to provide additional details on the financial impact of the transaction, including pro forma results, during its second quarter 2026 earnings call. Rothschild & Co. and Fenwick & West LLP advised CareDx, while TD Cowen and Kahn Partners advised Eurobio Scientific.